X0303 4 2010-03-01 0000729922 OSI PHARMACEUTICALS INC OSIP 0001314821 LUNDEMOSE ANKER MD, PH.D, DSC C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD NEW YORK NY 11747 1 EVP, Corp. Dev & Strategic Pln Common Stock 2010-03-01 4 M 0 15200 35.10 A 46823 D Common Stock 2010-03-01 4 M 0 13000 29.77 A 59823 D Common Stock 2010-03-01 4 S 0 29200 55.20 D 30623 D Stock Option (Right to Buy) 35.10 2010-03-01 4 M 0 15200 0 D 2005-02-11 2014-02-10 Common Stock 15200 0 D Stock Option (Right to Buy) 29.77 2010-03-01 4 M 0 13000 0 D 2007-06-13 2013-06-12 Common Stock 13000 5000 D Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 3, 2009. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.32 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. One third of the stock options became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months. 25% of the option became exercisable one year after the date of grant and the remainder vests ratably on an annual basis over the succeeding 3 years. Includes only options with the same termination date. /s/ Pierre Legault, attorney-in-fact for Dr. Lundemose 2010-03-03